Evidence map›Paper›PMID 36518253›Full record

Trial reportFrontiers in endocrinology2022

Health-related quality of life in boys with constitutional delay of growth and puberty.

Laura Kariola, Tero Varimo, Hanna Huopio, Sirpa Tenhola, Raimo Voutilainen, Silja Kosola, Jorma Toppari, Harri Sintonen, Päivi J Miettinen, Taneli Raivio and 1 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Laura KariolaHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Tero VarimoHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Hanna HuopioKuopio University Hospital, Kuopio, Finland.
Sirpa TenholaDepartment of Pediatrics, Kymenlaakso Central Hospital, Kotka, Finland.
Raimo VoutilainenKuopio University Hospital, Kuopio, Finland.
Silja KosolaHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Jorma ToppariInstitute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland.
Harri SintonenDepartment of Public Health, University of Helsinki, Helsinki, Finland.
Päivi J MiettinenHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Taneli RaivioHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Matti HeroHelsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland.
Helsinki University Hospital · FIKuopio University Hospital · FIUniversity of Helsinki · FIKymenlaakson keskussairaala · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Constitutional delay of growth and puberty (CDGP) is the most common reason for delayed puberty in healthy male adolescents. The main indication for medical treatment for this condition is psychosocial burden. However, to the best of our knowledge, no previous study has addressed the impact of puberty-promoting treatment on health-related quality of life (HRQoL) among boys with CDGP. Methods: We investigated HRQoL in 22 boys with CDGP, who participated in a randomized controlled trial in four Finnish pediatric endocrinology outpatient clinics between 2013 and 2017. The boys were randomized to receive either aromatase inhibitor letrozole (2.5mg/day; n=11) or intramuscular testosterone (1mg/kg/every 4 weeks; n=11) for 6 months and followed up to 12 months. HRQoL was assessed with a generic self-assessment 16D Results: At baseline, the mean 16D score of the CDGP boys was similar to the age-matched reference population (0.95 vs 0.96, p=0.838). However, the physical appearance score (satisfaction with general appearance, height and weight) was significantly lower in the CDGP boys (0.75 vs 0.92, p=0.004) than their peers. Twelve months after treatment, Appearance had improved significantly (0.75 vs 0.87, p=0.004) and no HRQoL dimension was inferior compared to the age-matched reference population. Discussion: In terms of HRQoL, the main impact of delayed puberty was dissatisfaction with physical appearance. Puberty promoting therapy was associated with a positive change in perceived appearance, with no clear difference between low-dose testosterone and letrozole treatments.

Indexed as

Puberty, DelayedAdolescentChildHumansLetrozoleMalePubertyQuality of LifeTestosteroneLetrozoleTestosterone16Dconstitutional delay of growth and pubertydelayed pubertyhealth-related quality of lifeletrozoletestosterone

Identifiers

PMID36518253
PMCPMC9743641
OpenAlexW4310172303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.